Healthcare
Synairgen plc(SYGGF)
Live Price
Offline$0.0001
+0.00% today
1Y Change
+0.00%
Window
Jun 23, 2025 → Jun 9, 2026
- Market Cap
- $10.00M
- Revenue Growth
- 0.0%
- EPS Growth
- +19.1%
- Dividend Yield
- 0.0%
Coverage: 242 bars · Jun 23, 2025 → Jun 9, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Synairgen plc (SYGGF) is a Healthcare stock with a market cap of $10.00M and listed on OTC. The stock last traded around $0.00 and up 0.0% across the available one-year price window (Jun 23, 2025 → Jun 9, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +19.1%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +19.1%, free cash flow +4.0% with operating margin 0.0% and ROIC -70.8%. Stock Foundry combines SYGGF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +19.1%, while operating margin sits near 0.0%.
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SYGGF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SYGGF Max Drawdown
-97.50%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SYGGF and SPY.
Company Overview
Synairgen plc
Other OTC
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease; and LOXL2 inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF) disease. The company has a licensing and collaboration agreement with Pharmaxis Ltd. to develop a LOXL2 inhibitor. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.
- Leadership
- Joseph Tregonning Colliver
- IPO Date
- Jul 20, 2020
- Employees
- 36
- Street Address
- Mailpoint 810
- Mailing
- Southampton, SO16 6YD
- Region
- Southampton, GB
- Reporting Currency
- USD
- Investor Line
- 44 23 8051 2800
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- —
- EV/EBITDA
- —
- Price/Sales
- —
- Price/Book
- 0.2
Growth
- Revenue
- 0.0%
- EPS
- +19.1%
- Free Cash Flow
- +4.0%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -51.1%
- ROIC
- -70.8%
Balance Sheet
- Debt/Equity
- —
- Current Ratio
- 9.01
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.